权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Regulatory T Cells in Alzheimer's Disease

阿尔茨海默病中的调节性 T 细胞

基本信息

批准号：
10515396
负责人：
Michael Archibald Farrar
金额：
$ 76.88万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-16 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10515396
关键词：
Adoptive Transfer Affect Age-Months Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Applications Grants Attenuated Birds Brain Case Study Cells Characteristics Comparative Study Diphtheria Toxin Disease Disease Progression FOXP3 gene Functional disorder Future Goals Human IL2 gene IL2RA gene Immune response Inflammation Inflammatory Interferons Investigation Kinetics Knowledge Label Location Microglia Modeling Mouse Strains Mus NRP1 gene Nervous System Trauma Outcome Pathogenesis Pathologic Play Population Process Proteomics Protocols documentation Regulatory T-Lymphocyte Reporter Role Symptoms T cell response T-Lymphocyte T-Lymphocyte Subsets Testing Time Tissue Model Tissues Transgenic Mice Work adaptive immune response base clinically relevant improved outcome in vivo mouse model neuroinflammation novel prevent repaired single-cell RNA sequencing systemic inflammatory response transcriptomics

项目摘要

PROJECT SUMMARY Recent studies have demonstrated that the adaptive immune response plays an important role Alzheimer’s disease (AD) progression by promoting a pro-inflammatory state in the brain. This inflammatory process involves T cell and microglial cell activation. Such inflammatory processes are typically suppressed by a subset of T cells called regulatory T cells (Tregs). Significantly, Treg dysfunction is associated with AD in humans and in mouse models of AD. In addition to decreased Tregs in AD cases, studies have demonstrated that systemic depletion of Tregs exacerbates early AD pathology, while an increase in Tregs attenuates early AD pathology in transgenic mouse models of AD. However, these previous studies come with important caveats. First, all studies involving Treg depletion focused on studies in young mice at early stages of AD pathology, which may not be a clinically relevant time-point. Second, studies using FOXP3-DTR mice and diphtheria toxin to selectively deplete Tregs deplete Tregs everywhere and induce body-wide inflammation. This makes it difficult to assess whether worse outcomes observed in AD upon “Treg depletion” are specific to an effect of Tregs in the brain or due to massive systemic inflammation. Moreover, the types of Tregs that accumulate during AD progression, and their functional role in disease progression, particularly in brain, are also unknown. Thus, major gaps in our knowledge are (i) what types of Tregs are found in the brain during steady-state and in Alzheimer’s disease and, (ii) what role Tregs or distinct subsets of Tregs play in ameliorating AD. Our preliminary studies demonstrate that Tregs in tissues are quite diverse and that distinct Treg subsets occupy inflamed tissues with different kinetics. Most notably, we identified a novel population of Tregs, called ISG-Tregs, that accumulate in tissues with IFN-driven inflammation. Previous studies of AD demonstrate that type I IFN is a characteristic of AD, that it exacerbates neurological damage in AD models, and plays an important role in initiating neuroinflammation and promoting AD progression. Thus, ISG-Tregs may play a critical role in AD progression. The goal of this proposal is to identify the subsets of Tregs present in the brain, and identify where those subsets are located within the brain, during AD progression, and establish murine models to directly test the function of Tregs and Treg subsets in AD. We will use scRNA-Seq and spatial proteomic/transcriptomic approaches to characterize Tregs during AD progression. Using a novel Treg reporter/deleter mouse strain that we developed we will also develop new mouse models that will allow us to study the function of brain Tregs, or select brain Treg subsets, on AD progression. We will also provide important information regarding the pathological role of Treg at different stages of AD in vivo. These studies will allow us to characterize the types of Tregs present in AD, establish their localization in the brain during disease progression, and develop models that will allow us to establish their functional role in ameliorating or exacerbating Alzheimer’s disease in the future. Such information will prove critical for better implementation of Treg-based therapies to improve outcomes in Alzheimer’s disease.

项目总结